Evidence map›Paper›PMID 40894688›Full record

ArticlebioRxiv : the preprint server for biology2025

Dose-dependent interferon programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination.

Giray Naim Eryilmaz, Yilmaz Yucehan Yazici, Radu Marches, Eleni P Mimitou, Lisa Kenyon-Pesce, Kim Handrjek, Sonia Jangra, Michael Schotsaert, Adolfo García-Sastre, George A Kuchel and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Giray Naim EryilmazThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Yilmaz Yucehan YaziciThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Radu MarchesThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Eleni P MimitouImmunai, New York, NY, USA.
Lisa Kenyon-PesceUConn Center on Aging, UConn Health, Farmington, CT, USA.
Kim HandrjekDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sonia JangraDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
George A KuchelUConn Center on Aging, UConn Health, Farmington, CT, USA.
Jacques BanchereauThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Duygu UcarThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

Funding

SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2M
Research Education ComponentP30AG067988 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Richard H Fortinsky, GEORGE A KUCHEL · 2021 to 2026
$9.5M
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacyR01AI160706 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2022 to 2025
$2.9M
High-resolution single cell profiling of vaccine responsiveness in the elderlyR01AI142086 · NIAID · JACKSON LABORATORY · PI UCAR, DUYGU · 2019 to 2023
$2.9M
NIAID NIH HHS R01 AI142086NIAID NIH HHS R01 AI160706NIAID NIH HHS U19 AI135972NIA NIH HHS P30 AG067988
6 · The paper itself

Abstract

The SARS-CoV-2 pandemic provided a rare opportunity to study how human immune responses develop to a novel viral antigen delivered through different vaccine platforms. However, to date, no study has directly compared immune responses to all three FDA-approved COVID-19 vaccines at single-cell multi-omic resolution. We longitudinally profiled SARS-CoV-2-naïve adults (n=31) vaccinated with BNT162b2, mRNA-1273, or Ad26.COV2.S, integrating plasma cytokines, antibody titers, and single-cell multi-omic data (DOGMA-seq). We discovered a distinct, transient interferon program (ISG-dim) that emerged specifically 1-2 days after the first mRNA dose in ~10% of myeloid cells. This state was characterized by ISGF3 complex activation and its target genes (e.g.,

Identifiers

PMID40894688
PMCPMC12393322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.